TheraRadar
← Back
Data updated: May 24, 2026

Pfizer

PFE Big Pharma
OncologyInfectious DiseaseImmunology Execution: Good

Global pharmaceutical leader with blockbuster franchises in vaccines (Prevnar, Comirnaty), cardiovascular (Eliquis), and oncology. Known for rapid COVID-19 vaccine development and strategic acquisitions including Seagen.

$58.5B
Revenue (2024)
$145.0B
Market Cap
-
Trials
9
New Drugs (2yr)
Modality:
85 Small Molecules 12 Biologics
Novel Drugs (2017-2024):
14 Novel Approvals 3 First-in-Class 7 Orphan Drug 4 Breakthrough

Pfizer at a Glance

  • Leading 42 drug targets across portfolio
  • Fast trial execution (11 months median completion)

Upcoming FDA Decisions

Full Calendar →
Jun 29, 2026 — HYMPAVZI (marstacimab)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
BENDAMUSTINE HYDROCHLORIDE NDA
2025-07-03
bendamustine hydrochloride
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
HYMPAVZI BLA
2024-10-11
marstacimab-hncq
Hemophilia A
BORTEZOMIB NDA
2024-08-26
bortezomib

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 37%
29 drugs Phase 3: 79 Phase 2: 107 Phase 1: 206
Infectious Disease 22%
27 drugs Phase 3: 53 Phase 2: 53 Phase 1: 52
Immunology 19%
12 drugs Phase 3: 54 Phase 2: 62 Phase 1: 49
Neurology 12%
8 drugs Phase 3: 37 Phase 2: 30 Phase 1: 44
Dermatology 10%
18 drugs Phase 3: 22 Phase 2: 23 Phase 1: 16

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

245
Phase 3
275
Phase 2
367
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2026
PF-06821497
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Estimated · fresh NCT06551324
Q3 2026
nirmatrelvir
COVID-19
Estimated · aging NCT05261139
Q3 2026
Elranatamab
Multiple Myeloma
Estimated · fresh NCT06152575
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • IBRANCE leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 257/390 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges